<DOC>
	<DOCNO>NCT01947881</DOCNO>
	<brief_summary>The purpose study identify Diabetic Macular Edema ( DME ) characteristic eye show different response treatment anti-VEGF ( vascular endothelial growth factor ) injection Lucentis .</brief_summary>
	<brief_title>Characterization Eyes With Diabetic Macular Edema That Show Different Treatment Response Intravitreal Anti-VEGF ( CHARTRES )</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Patients 40 year age old . Type 2 Diabetes Mellitus . Glycosylated hemoglobin ( HbA1C ) ≤ 12 % screen visit . Presence clinically significant DME involve center ( fovea ) diagnose least one eye eligible antiVEGF treatment opinion investigator . If eye eligible , one bad visual acuity , assess screen visit , select study eye . Visual impairment due DME BCVA ≥ 39 letter ≤ 73 letter ( ≥ 20/160 ≤ 20/40 ) . Central subfield thickness ≥ 300µm . Presence ocular disease DME study eye may confound study result , Proliferative Retinopathy . Previous treatment vitrectomy intravitreous injection triancinolone antiVEGF drug study eye . Any previous laser photocoagulation ( panretinal focal ) study eye within 6 month prior inclusion study . Active intraocular inflammation ( grade trace ) either eye screening visit . Any active infection ( e.g . conjunctivitis , keratitis , scleritis , uveitis , endophthalmitis ) either eye screening visit . Important refractive error ( myopia &gt; 6D ) opacification clear medium interferes image evaluation . Patients renal failure systemic condition , opinion investigator , would preclude schedule study visit , completion study safe administration study medication . Other criteria opinion investigator condition evaluation purpose .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Diabetic Macular Edema</keyword>
	<keyword>anti-VEGF</keyword>
	<keyword>Treatment Response</keyword>
</DOC>